文献速递腹部介入DSACTMR

经动脉化疗栓塞联合分子靶向治疗肝细胞癌合并门静脉癌栓患者的预后评估——ABPS评分的开发与验证

Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score.
PubMed 文献 · Acad Radiol · 2024-03-20

本研究基于16家机构384例接受TACE联合分子靶向治疗的肝细胞癌合并门静脉癌栓患者,回顾性开发并验证了ABPS评分(白蛋白-胆红素分级、门静脉癌栓分型、系统性免疫炎症指数),并在200例前瞻性队列患者中进行外部验证。ABPS评分与生存结局和影像学缓解相关,C指数为0.802,显著优于HAP、6-12、Up to 7和ALBI评分系统。

要点

  • ABPS评分仅纳入ALBI分级、PVTT分型和SII三项指标,总分0-3分,操作简便。
  • ABPS评分将患者分为A(0分)、B(1-2分)、C(3分)三组风险分层。
  • ABPS评分C指数为0.802,显著优于HAP、6-12、Up to 7和ALBI评分系统。

核心结论

  • ABPS评分与接受TACE联合分子靶向治疗的HCC合并PVTT患者的生存结局和影像学缓解密切相关,可能作为指导治疗选择的有价值工具。

研究设计与样本

  • 回顾性分析384例在16家不同机构接受TACE联合分子靶向治疗的HCC合并PVTT患者,用于开发和验证ABPS评分。
  • 外部验证采用前瞻性队列研究纳入的200例患者数据。

诊断标准与关键数值

  • ABPS评分范围0-3分:ALBI分级1级计0分、2级计1分;PVTT I-II型计0分、III-IV型计1分;SII <550×10^12计0分、≥550×10^12计1分。
  • 根据ABPS评分分为三组:ABPS-A(0分)、ABPS-B(1-2分)、ABPS-C(3分)。
  • ABPS评分系统C指数为0.802,显著优于HAP评分(0.758)、6-12评分(0.712)、Up to 7评分(0.683)和ALBI评分(0.595),均P < 0.05。

临床应用与阅片要点

  • ABPS评分可用于接受TACE联合分子靶向治疗的HCC合并PVTT患者的风险分层和预后评估。
  • ABPS评分可能作为指导这些患者治疗选择的有价值工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Transarterial chemoembolization (TACE) plus molecular targeted therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). A robust model for outcome prediction and risk stratification of recommended TACE plus molecular targeted therapies candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients.

METHODS: A retrospective analysis was conducted on 384 patients with HCC and PVTT who underwent TACE plus molecular targeted therapies at 16 different institutions. We developed and validated a new prognostic score which called ABPS score. Additionally, an external validation was performed on data from 200 patients enrolled in a prospective cohort study.

RESULTS: The ABPS score (ranging from 0 to 3 scores), which involves only Albumin-bilirubin (ALBI, grade 1: 0 score; grade 2: 1 score), PVTT(I-II type: 0 score; III-IV type: 1 score), and systemic-immune inflammation index (SII,<550 × 1012: 0 score; ≥550 × 1012: 1 score). Patients were categorized into three risk groups based on their ABPS score: ABPS-A, B, and C (scored 0, 1-2, and 3, respectively). The concordance index (C-index) of the ABPS scoring system was calculated to be 0.802, significantly outperforming the HAP score (0.758), 6-12 (0.712), Up to 7 (0.683), and ALBI (0.595) scoring systems (all P < 0.05). These research findings were further validated in the external validation cohorts.

CONCLUSION: The ABPS score demonstrated a strong association with survival outcomes and radiological response in patients undergoing TACE plus molecular targeted therapy for HCC with PVTT. The ABPS scoring system could serve as a valuable tool to guide treatment selection for these patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Liu K, Zheng X, Dai J, et al. Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score. Acad Radiol. 2024. PMID: 38508935. doi:10.1016/j.acra.2024.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。